Digital diabetes administration firm Glooko has acquired Paris-based DIABNEXT, a fellow diabetes care platform.
DIABNEXT’s app tracks affected person diabetes metrics, permitting suppliers to observe that information and supply care remotely. Glooko mentioned it would provide its personal platform and DIABNEXT, rebranded as Glooko XT, for the French market.
“We’re more than happy to welcome the DIABNEXT group to Glooko and particularly excited so as to add their well-regarded product to Glooko’s portfolio, together with their experience within the diabetes neighborhood in France,” Glooko CEO Russ Johannesson mentioned in an announcement.
“The addition of DIABNEXT expands our choices with a novel platform that may assist us higher customise the affected person expertise and enhance well being outcomes for folks with diabetes. Glooko’s acquisition of DIABNEXT additional cements our dedication to extend our world presence and proceed to drive progressive options.”
That is Glooko’s second acquisition this 12 months. In January, the corporate introduced it had bought Berlin-based xbird, maker of AI-based diabetes care instruments. The corporate raised $30 million in Sequence D funding final 12 months.
Papa, which provides in-home help for seniors or different weak populations, introduced Wednesday it is increasing into the employer market.
The startup mentioned partnerships with employers will present caregiving help for employees who need to help aged, chronically unwell or disabled members of the family along with their paid work.
“For workers, the inconceivable balancing act between one’s work and household roles impacts them, their dependents, and finally their employer,” Andrew Parker, founder and CEO of Papa, mentioned in an announcement.
“Papa has proven success with Medicare Benefit and Medicaid members when it comes to lowered loneliness and improved well being, and we consider there’s great alternative to increase our mannequin to versatile household care, for assist when, the place, and the way it’s most wanted.”
In late 2021, Papa scooped up $150 million in Sequence D funding.
Digital chronic-condition administration firm Lark Well being is growing an AI-enabled platform for stopping and managing atherosclerotic heart problems (ASCVD) and coronary artery illness (CAD) in partnership with Roche Diagnostics.
The Lark Coronary heart Well being program, which is about to launch later this 12 months, makes use of the ideas of cognitive behavioral remedy to offer teaching round wholesome behaviors and decreasing stress.
“Lark Coronary heart Well being will assist these at excessive danger stop and actively handle heart problems via customized digital teaching,” cofounder and CEO Julia Hu mentioned in an announcement. “By leveraging our AI expertise, we will ship significant and fascinating care at an unprecedented scale, and this collaboration with Roche Diagnostics will help the growth of our confirmed tech platform into one of many costliest continual illness markets.”